Azafaros
A clinical-stage company aiming to build a pipeline of disease-modifying therapeutics to offer new treatment options.
The company’s lead clinical-staged program is AZ-3102, a small molecule, orally available, brain penetrant azasugar, with the potential to treat GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) and Niemann-Pick disease type C.
Azafaros is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures, BioMedPartners and Schroders Capital.
Latest Azafaros News & Features
20 March 2023
20 February 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze